NCT06692972 The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
| NCT ID | NCT06692972 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China-Japan Friendship Hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-12-25 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-12-25 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old; 2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy; 3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy); 4. The target lesion of the lung receiving radiotherapy can be measured; 5. Imaging data can be obtained before and after radiotherapy; 6. Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose. Exclusion Criteria： 1. Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment; 2. The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy)； 3. Required imaging data cannot be obtained; 4. Other conditions considered by the investigator to be inappropriate for enrollment.
Contact & Investigator
Guangying Zhu, M.D.
PRINCIPAL INVESTIGATOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT06692972 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06692972 currently recruiting?
Yes, NCT06692972 is actively recruiting participants. Contact the research team at zryyfa@163.com for enrollment information.
Where is the NCT06692972 trial being conducted?
This trial is being conducted at Beijing, China, Wuhan, China.
Who is sponsoring the NCT06692972 clinical trial?
NCT06692972 is sponsored by China-Japan Friendship Hospital. The principal investigator is Guangying Zhu, M.D. at China-Japan Friendship Hospital. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.